EA201692564A1 - Комбинированная терапия - Google Patents

Комбинированная терапия

Info

Publication number
EA201692564A1
EA201692564A1 EA201692564A EA201692564A EA201692564A1 EA 201692564 A1 EA201692564 A1 EA 201692564A1 EA 201692564 A EA201692564 A EA 201692564A EA 201692564 A EA201692564 A EA 201692564A EA 201692564 A1 EA201692564 A1 EA 201692564A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combined therapy
alpha
olarathumab
doxorubicin
bind
Prior art date
Application number
EA201692564A
Other languages
English (en)
Inventor
Ник Лоизос
Гаурав Д. Шах
Original Assignee
Имклон Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Имклон Ллк filed Critical Имклон Ллк
Publication of EA201692564A1 publication Critical patent/EA201692564A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В настоящем изобретении предложена комбинация антител человека, которые связываются с рецептором альфа фактора роста тромбоцитов человека (PDGFR альфа), предпочтительно оларатумаба и доксорубицина, в качестве лекарственного средства для лечения саркомы мягких тканей.
EA201692564A 2014-07-03 2015-06-26 Комбинированная терапия EA201692564A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462020427P 2014-07-03 2014-07-03
PCT/US2015/037892 WO2016003789A1 (en) 2014-07-03 2015-06-26 Combination therapy

Publications (1)

Publication Number Publication Date
EA201692564A1 true EA201692564A1 (ru) 2017-09-29

Family

ID=53514434

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692564A EA201692564A1 (ru) 2014-07-03 2015-06-26 Комбинированная терапия

Country Status (18)

Country Link
US (1) US20170129958A1 (ru)
EP (1) EP3164154A1 (ru)
JP (2) JP6446478B2 (ru)
KR (1) KR20170012481A (ru)
CN (1) CN106470698A (ru)
AP (1) AP2016009649A0 (ru)
AU (1) AU2015284526B2 (ru)
BR (1) BR112016030291A2 (ru)
CA (1) CA2950936A1 (ru)
EA (1) EA201692564A1 (ru)
IL (1) IL249240A0 (ru)
MA (1) MA40367A (ru)
MX (1) MX2016017396A (ru)
NZ (1) NZ727147A (ru)
SG (1) SG11201610931YA (ru)
TW (1) TWI646974B (ru)
WO (1) WO2016003789A1 (ru)
ZA (1) ZA201608217B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2822084T3 (es) * 2016-07-28 2021-04-29 Elanco Us Inc Anticuerpo antirreceptor alfa del factor de crecimiento derivado de plaquetas canino
US20240132602A1 (en) * 2021-03-19 2024-04-25 Eli Lilly And Company Methods of treating cancer with pdgfr alpha inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2238982B8 (en) * 2003-06-27 2013-01-16 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CA2678008C (en) 2005-06-17 2013-07-30 Imclone Systems Incorporated Methods of treating a secondary bone tumor with anti-pdgfralpha antibodies
AU2009214727B2 (en) * 2008-02-12 2014-12-11 Tosk, Incorporated Doxorubicin adjuvants to reduce toxicity and methods for using the same
HUE024872T2 (en) * 2008-11-22 2016-02-29 Hoffmann La Roche Use of anti-vegf antibody in combination with chemotherapy to treat breast cancer
JP2013526852A (ja) * 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー

Also Published As

Publication number Publication date
AU2015284526B2 (en) 2018-05-17
TWI646974B (zh) 2019-01-11
AP2016009649A0 (en) 2016-12-31
SG11201610931YA (en) 2017-01-27
CN106470698A (zh) 2017-03-01
KR20170012481A (ko) 2017-02-02
NZ727147A (en) 2018-05-25
ZA201608217B (en) 2019-05-29
MA40367A (fr) 2017-05-10
JP2019014724A (ja) 2019-01-31
CA2950936A1 (en) 2016-01-07
MX2016017396A (es) 2017-05-01
WO2016003789A1 (en) 2016-01-07
JP2017520576A (ja) 2017-07-27
JP6446478B2 (ja) 2018-12-26
US20170129958A1 (en) 2017-05-11
IL249240A0 (en) 2017-02-28
TW201611844A (en) 2016-04-01
EP3164154A1 (en) 2017-05-10
AU2015284526A1 (en) 2016-12-22
BR112016030291A2 (pt) 2017-11-14

Similar Documents

Publication Publication Date Title
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
EA201792414A1 (ru) Антитела против cd166, активируемые антитела против cd166 и способы их применения
EA201792413A1 (ru) Антитела против cd71, активируемые антитела против cd71 и способы их применения
EA201791093A1 (ru) Антитела к cd47, способы и применение
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201892294A1 (ru) Антитела и композиции против tim-3
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
PE20180927A1 (es) Moleculas de union a lag-3 y metodos de uso de las mismas
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
MX2018014175A (es) Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
EA201790932A1 (ru) Дозировка и введение нефукозилированных анти-cd40 антител
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MY192927A (en) Fused bicyclic compounds for the treatment of disease
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
EA201692109A1 (ru) Варианты антител к фактору d и их применение
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
EA201691541A1 (ru) Новые анти-baff антитела
EA201891299A1 (ru) Терапевтические антитела к cd9
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA201692395A1 (ru) Новые соединения